Consumer health company Haleon has published a first-of-its kind study highlighting the significant positive impact that its nasal decongestant Otrivin can have on patients’ quality of life.
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.